



(51) International Patent Classification:

A61K 31/194 (2006.01) A61P 3/04 (2006.01)

A61K 31/198 (2006.01)

(21) International Application Number:

PCT/IB2018/055428

(22) International Filing Date:

20 July 2018 (20.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

102017000087376 28 July 2017 (28.07.2017) IT

(71) Applicant: PROFESSIONAL DIETETICS S.P.A.

[IT/IT]; Via Ciro Menotti 1/A, I-20129 Milano (IT).

(72) Inventor: GIORGETTI, Paolo Luca Maria; Via Fabio

Filzi, 41, I-20124 Milano (IT).

(74) Agent: CESA, Roberta; c/o Buzzi, Notaro & Antonielli

d'Oulx S.r.l., Corso Vittorio Emanuele II, 6, I-10123 Torino (IT).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYS-FUNCTION-RELATED DISEASES

(57) Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.



WO 2019/021137 A1

"Compositions comprising amino acids for use in the
treatment of mitochondrial dysfunction-related
diseases"

5

Field of the invention

The present description relates generally to
compositions comprising amino acids. More particularly,
the description relates to compositions comprising
10 amino acids for use in medicine, in particular for use
in the treatment of diseases related to mitochondrial
dysfunction.

Background

15 Mitochondria are cellular organelles which primary
function is oxidative phosphorylation, a process
through which energy derived from metabolism of glucose
or fatty acids is converted to adenosine triphosphate
(ATP). ATP is then used to drive various energy-
20 requiring biosynthetic reactions and other metabolic
activities.

Mitochondrial dysfunction may affect any tissue with a
resulting large variety of symptoms, depending on the
extent to which the different tissues are involved.

25 Diseases arising from mitochondrial dysfunction may
include for example, mitochondrial swelling due to
mitochondrial membrane potential malfunction,
functional disorders due to oxidative stress such as by
the action of reactive oxygen species (ROS) or free
30 radicals, functional disorders due to genetic mutations
and diseases due to functional deficiency of oxidative
phosphorylation mechanisms for energy production.

Mitochondria deteriorate with age, losing respiratory
activity, accumulating damage to their DNA (mtDNA) and
35 producing excessive amounts of reactive oxygen species

(ROS).

Recent evidence points to involvement of mitochondrial dysfunction in several diseases, including the age-related metabolic and cardiovascular disorders (atherosclerosis), in addition to the major neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease and to chronic obstructive pulmonary disease (COPD).

Mitochondrial dysfunction has also been found in obesity and related disorders, including type 2 diabetes mellitus, high blood pressure, dyslipidemia, heart failure, kidney disease and osteoporosis.

Notably, sarcopenia, defined as one of the most important causes of functional decline and loss of independence in older adults due to involuntary loss of skeletal muscle mass and strength, and key feature of the so-called frailty syndrome, is due to reduced mitochondrial mass and function. Other muscle wasting diseases and disorder are known, including, for example, cachexia. Cachexia or wasting syndrome is defined as an unintentional loss of body weight, muscle atrophy, fatigue, and weakness. Cachexia is seen in people with cancer, AIDS, coeliac disease, COPD, multiple sclerosis, rheumatoid arthritis, congestive heart failure, tuberculosis and anorexia nervosa. No drugs or nutrients have been found to prevent and/or treat this condition.

Thus, given the worldwide obesity epidemics and increasing population ageing, the most frequent patients in the next future will be sarcopenic, obese elderly subjects.

Obesity and its associated diseases, such as insulin resistance and type 2 diabetes, are nowadays a major health problem, with more than 1.4 billion overweight adults (World Health Organization. Obesity and

overweight. WHO Media Centre). Among them, ~500 million are obese and 40 million children under the age of 5 are currently classified as overweight or obese (World Health Organization. Obesity and overweight. WHO Media Centre).

From a metabolic point of view, obesity takes place when energy intake exceeds energy expenditure (EE) consequent to decreased mitochondrial function; therefore, besides dietary interventions aimed to decrease energy intake, another approach is to increase energy expenditure by means, for example, of physical exercise. However, this is not a simple task, especially for obese individuals, which often show obesity-associated muscle dysfunction (Wells et al., 2008).

Therefore, there is a growing need for new therapeutic approaches aimed to achieve weight loss and reduce the social and medical impact of this disease.

Summary of the invention

The present description has the aim of providing new amino acid based compositions particularly effective in increasing mitochondrial function and thus in the treatment of the obesity and related disorders.

According to the present description, the above object is achieved thanks to the subject matter specifically recalled in the ensuing claims, which are understood as forming an integral part of this disclosure.

An embodiment of the present description provides a composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

In one or more embodiments, the active agent of the composition further contains one or more amino acids selected in the group consisting of histidine, phenylalanine, methionine, tryptophan, cysteine and tyrosine.

In one or more embodiments, the compositions herein disclosed may be used in medicine.

In a preferred embodiment, the compositions may be used in the treatment and/or prevention of a mitochondrial dysfunction-related disease, wherein said disease is obesity.

Brief description of the drawings

The invention will now be described, by way of example only, with reference to the enclosed figures, wherein:

- Figure 1 shows the content of mitochondrial DNA (mtDNA) analysed by means of quantitative PCR in HL-1 cardiomyocytes treated with different amino acid based compositions for 48 hours (48 hr, 2 d). The quantitative PCR is performed in triplicate and normalized to genomic-DNA coding for the GAPDH (n = 3, mean $\pm$ SEM). Value of untreated cells (CT) is taken as 1.0 (*p < 0.05 vs. untreated cells, #p < 0.05 vs. BCAAem and B2).

- Figure 2 shows the mRNA levels of mitochondrial biogenesis marker (Tfam, PGC-1 α , Cyt c) levels analysed by means of quantitative PCR in HL-1 cardiomyocytes treated with amino acid based compositions for 24 hr (1 d). Quantitative PCR is performed in triplicate and normalized to GAPDH (n = 3, mean $\pm$ SEM). *p < 0.05 vs. untreated cells, expressed as 1.0. #p < 0.05 vs. BCAAem.

- Figure 3 shows the mRNA levels of mitochondrial biogenesis marker (Tfam, PGC-1 α , Cyt c) analysed by quantitative PCR in HL-1 cardiomyocytes

treated with amino acid based compositions for 48 hr (2 d). Quantitative PCR is performed in triplicate and normalized to GAPDH (n = 3, mean $\pm$ SEM). *p < 0.05 vs. untreated cells, expressed as 1.0. #p < 0.05 vs.

5 BCAAem.

- Figure 4 shows the mRNA levels of Krüppel-like factor 15 (KFL15) and mitochondrial matrix-targeted protein phosphatase 2C family member (PP2CM) which are proteins regulating the catabolism of the branched chain amino
10 acids (BCAA). PP2CM and KFL15 have been analysed by quantitative PCR in HL-1 cardiomyocytes treated with amino acid based compositions for 24 hr (1 d) or 48 hr (2 d). Quantitative PCR is performed in triplicate and normalized to GAPDH (n = 3, mean $\pm$ SEM). *p < 0.05 vs.
15 untreated cells, expressed as 1.0; #p < 0.05 vs. BCAAem and B2.

- Figure 5 shows an evaluation of the oxygen consumption rate (OCR). Oxygen consumption in HL-1 cardiomyocytes treated with amino acid based
20 compositions or DETA-NO for 48 hr. ****p < 0.001 vs. untreated cell; ###p < 0.001 vs. BCAAem and B2.

- Figure 6 shows UCP1 expression in immortalized brown adipocytes (Seale et al., 2007) after 48 hr (2d) treatment. CT: untreated, control cells. Value of
25 untreated cells (CT) is taken as 1.0. * significant vs. CT. # significant vs. BCAAem; RT-PCR is performed in triplicate and normalized to GAPDH (n = 3, mean $\pm$ SEM).

- Figure 7 shows PGC-1 α expression in immortalized brown adipocytes after 48 hr (2d) treatment. CT:
30 untreated, control cells, Value of untreated cells (CT) is taken as 1.0. * significant vs. CT. # significant vs. BCAAem. PCR is performed in triplicate and normalized to GAPDH (n = 3, mean $\pm$ SEM).

35 **Detailed description of preferred embodiments**

In the following description, numerous specific details are given to provide a thorough understanding of embodiments. The embodiments can be practiced without one or more of the specific details, or with other
5 methods, components, materials, etc. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the embodiments.

Reference throughout this specification to "one
10 embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various
15 places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. The headings provided
20 herein are for convenience only and do not interpret the scope or meaning of the embodiments.

In one or more embodiments, the composition herein disclosed comprises an active agent, the active agent containing the amino acids leucine, isoleucine, valine,
25 threonine, lysine and the acids citric acid, succinic acid, malic acid.

A composition comprising amino acids - as disclosed in EP 2 196 203 B1 - was administrated in mammals as alternative solution to provide benefits of calory
30 restriction (CR); such based amino acid composition (referred to as "BCAAem" in the instant disclosure) has been shown to lead an increased mitochondrial biogenesis both in cardiac and skeletal muscles (D'Antona et al., 2010). These effects were mediated by
35 expression of endothelial nitric oxide synthase (eNOS)

and consequent nitric oxide (NO) production (D'Antona et al., 2010).

The Inventor of the instant application surprisingly found that by adding specific acids to a composition
5 comprising a similar combination of leucine, isoleucine, valine, threonine and lysine a significant increase in cell mitochondrial function, and thus in energy expenditure (EE), may be achieved.

The Inventor of the instant application tested a number
10 of compositions different in terms of acids contained therein and found that compositions comprising as active agent a combination of citric acid, succinic acid and malic acid with leucine, isoleucine, valine, threonine and lysine are very effective for the
15 indicated purposes. Indeed, compositions comprising the above stated active agent as well as compositions comprising the above stated active agent including further specific amino acids (listed in Table 1 below) are significantly more effective than the previously
20 tested amino acids based composition (BCAAM) in promoting mitochondrial biogenesis and function.

The compositions were tested on Cardiac Muscle Cell Line (HL-1), i.e. cells representing an *in vitro* model of the cardiac functionality. Results deriving from
25 analysis of these cardiomyocytes may be used to verify the efficacy of new compositions in the prevention of the heart failure.

In addition, the compositions herein disclosed were tested on immortalized brown adipocytes, an *in vitro*
30 model of brown fat. A recent discovery has been shown the occurrence of Brown Adipose Tissue (BAT) in humans (Trayhurn, 2016).

Contrary to white adipose tissue (WAT), which is mainly an energy storing organ in the form of fat
35 (triglycerides), brown adipose tissue (BAT) utilizes

energy from food to produce heat (thermogenesis), therefore enhancing energy expenditure (EE).

This process is activated in response to both environmental (i.e. cold exposure) and nutritional
5 (diet) cues, by means of increased expression and activity of the uncoupling protein 1 (UCP1; Cannon and Nedergaard, 2004).

The data provided in the instant application show the effectiveness of the compositions disclosed herein in
10 the increase of UCP1 expression thus confirming their usefulness in medicine, in particular in the treatment of obesity and related disorders, such as for example insulin resistance and type 2 diabetes.

In one or more embodiments, the composition herein
15 disclosed comprises an active agent, said active agent containing citric acid, succinic acid and malic acid in combination with leucine, isoleucine, valine, threonine, lysine, wherein the weight ratio between the total amount of citric acid, succinic acid and malic
20 acid and the total amount of the amino acids leucine, isoleucine, valine, threonine, lysine is comprised between 0.05 and 0.3, preferably between 0.1 and 0.25.

In one or more embodiments, the active agent may further comprise one or more amino acids selected in
25 the group consisting of histidine, phenylalanine, methionine, tryptophan, cysteine, tyrosine.

In a further embodiment, the active agent of the composition herein disclosed may also include aspartic acid and/or ornithine L-alpha ketoglutarate (OKG).

30 According to an embodiment, the composition comprises an active agent, the active agent consisting of leucine, isoleucine, valine, threonine, lysine, histidine, phenylalanine, methionine, tryptophan, cysteine and optionally tyrosine, as well as citric
35 acid, succinic acid and malic acid, said amino acids

being the sole amino acids contained in the composition.

In a further embodiment, the composition may comprise the amino acids isoleucine, leucine and valine in an amount between 35% and 65% by weight, preferably between 42% and 56% by weight with respect to the active agent weight.

In one or more embodiments, the weight ratio between leucine and citric acid is comprised between 5 and 1, preferably between 2.5 and 3.5.

In a further embodiment, the weight or molar amount of citric acid is higher than the weight or molar amount of each of malic acid and succinic acid. Preferably, the weight or molar amount of citric acid is higher than the weight or molar overall amount of malic acid plus succinic acid. In a further embodiment, the weight ratio between citric acid and the sum of malic acid and succinic acid is comprised between 1.0 and 4.0, preferably between 1.5 and 2.5. In a preferred embodiment, the citric acid:malic acid:succinic acid weight ratio is comprised between 10:1:1 and 2:1.5:1.5, preferably between 7:1:1 and 1.5:1:1, more preferably between 5:1:1 and 3:1:1.

According to some embodiments of the present disclosure, the preferred isoleucine:leucine molar ratio is comprised in the range 0.2-0.7, preferably in the range 0.30-0.60 and/or the preferred valine:leucine weight ratio is comprised in the range 0.2-0.70, preferably in the range 0.30-0.65.

In a further embodiment, the threonine:leucine molar ratio is comprised in the range of 0.10-0.90, preferably in the range 0.20-0.70 and/or the lysine:leucine weight ratio is comprised in the range of 0.20-1.00, preferably in the range 0.40-0.90.

In a preferred embodiment, the ratio between the

overall molar amount of citric acid, malic acid, succinic acid and the overall molar amount of methionine, phenylalanine, histidine and tryptophan is higher than 1.35.

5 In one or more embodiments, the weight ratio between the sum of citric acid, malic acid, succinic acid and the sum of the branched chain amino acids leucine, isoleucine, valine is comprised between 0.1 and 0.4, preferably between 0.15 and 0.35.

10 In a further embodiment, the overall weight amount of the branched chain amino acids leucine, isoleucine, valine plus threonine and lysine is higher than the overall weight amount of the three acids (citric acid, malic acid, succinic acid). Preferably, the weight
15 amount of the single acids (citric acid, succinic acid or malic acid) is less than the weight amount of each the single amino acids leucine, isoleucine, valine, threonine and lysine.

In a preferred embodiment, the weight ratio between the
20 sum of citric acid, malic acid, succinic acid and the sum of the branched chain amino acids leucine, isoleucine, valine plus lysine and threonine is comprised between 0.05 and 0.30, preferably between 0.10 and 0.25.

25 In a further embodiment, the overall molar amount of lysine and threonine is higher than the overall molar amount of the three acids citric acid, succinic acid, malic acid. Preferably, the ratio between the overall molar amount of the three acids citric acid, succinic
30 acid, malic acid and the overall molar amount of lysine and threonine is comprised between 0.10 and 0.70, preferably between 0.15 and 0.55.

In one or more embodiments, the composition herein disclosed further comprises vitamins, preferably
35 selected in the group of vitamins B, such as vitamin B₁

and/or vitamin B₆.

In a further embodiment of the present disclosure, the composition may include carbohydrates, additives and/or flavouring substances.

5 Furthermore, in particular when preparing the compositions according to the instant disclosure, and specifically the active agent, the amino acid arginine is preferably avoided.

10 In addition, further amino acids preferably excluded by the composition herein disclosed are serine, proline, alanine.

Such amino acids can be counterproductive or even harmful in some concentrations or stoichiometric ratios within the composition.

15 The amino acids disclosed in the instant description can be replaced by respective pharmaceutically acceptable derivatives, namely salts.

20 As will emerge clearly hereinafter, the administration of the compositions according to the present disclosure is particularly effective in promoting mitochondrial biogenesis and mitochondrial function.

In a preferred embodiment, the disclosed compositions may be used in the treatment and/or prevention of a mitochondrial dysfunction-related disease, wherein said
25 disease is obesity.

In a further embodiment, the disclosed compositions may be used in the treatment and/or prevention of a mitochondrial dysfunction-related disease, wherein said disease is an obesity-related disease, preferably
30 selected between insulin resistance and type 2 diabetes.

According to a further embodiment, the amino acid compositions may comprise pharmaceutically acceptable excipients, like for example proteins, vitamins,
35 carbohydrates, natural and artificial sweeteners and/or

flavoring substances. In a preferred embodiment, the pharmaceutically acceptable excipients may be selected from whey proteins, maltodextrins, fructose, calcium caseinate, fish oil, citric acid or salts thereof, 5 sucralose, sucrose esters, vitamin D3, group B vitamins.

For oral use, the compositions according to the description may be in the form of tablets, capsules, granules, gel, gelable powder, powder.

10 Further specifications, in terms of amounts and ratios among the various amino acids provided for by the compositions are contained in the attached claims, which form an integral part of the technical teaching provided herein in relation to the invention.

15

EXAMPLES

Table 1 shows different amino acid based compositions tested on HL-1 cells and on immortalized brown adipocytes as disclosed below.

20 Specifically, the BCAAem composition is the composition disclosed in EP 2 196 203 B1.

The composition named "B2" has as active agent a combination of amino acids similar to that of the BCAAem composition but further including citric acid.

25 Such a composition also comprises vitamins B1 and B6.

The compositions named alpha 5 (α 5), alpha 6 (α 6), alpha 7 (α 7) comprise an active agent containing amino acids and citric acid, succinic acid and malic acid. In addition, the alpha 7 composition's active agent also

30 comprises OKG (ornithine L- α ketoglutarate) and the amino acid aspartate (Acid L-aspartic).

Table 1

Compositions (%)	BCAAem	B2	$\alpha 5$	$\alpha 6$	$\alpha 7$
L-Leucine	30,01	25,9555	31,0885	22,4500	21,7188
L-Lysine HCl chlorhydrate	19,58	16,9346	16,903	21,1300	20,4380
L-Isoleucine	15	12,9778	10,3628	11,2300	10,8594
L-Valine	15	12,9778	10,3628	11,2300	10,8594
L-Threonine	8,4	7,2675	7,254	13,1000	12,6693
L-Cysteine	3,6	3,1147	3,1089	2,8100	2,7149
L-Histidine	3,6	3,1147	3,1089	2,8100	2,7149
L-Phenylalanine	2,4	2,0764	2,0726	1,8700	1,8099
L-Methionine	1,2	1,0382	1,0363	0,9400	0,9050
L-Tyrosine	0,72	0,6229	0,6218	-	-
L-Tryptophan	0,48	0,4153	2,0726	0,9400	0,9050
OKG(ornithine L- α ketoglutarate)	-	-	-	-	0,9050
Vitamin B1 (thiamine chlorhydrate)	-	0,004	0,004	0,0200	0,0163
Vitamin B6 (piridoxine chlorhydrate)	-	0,0038	0,0038	0,0200	0,0186
Citric acid anhydrous	-	13,4969	8,0001	7,6500	7,4025
Malic acid	-	-	2,0000	1,9200	1,8551
Acid L-aspartic	-	-	-	-	2,3529
Succinic acid	-	-	2,0000	1,9200	1,8551
Ratio					
Leucine:Isoleucine:Valine	2:1:1	2:1:1	3:1:1	2:1:1	2:1:1

- 5 The compositions of Table 1 above may be prepared first by sifting all the components with a 0.8 mesh. To obtain a pre-mixture, each ingredient (in an amount <10% by weight of the total amount) is put in a polyethylene bag together with a portion of L-lysine

HCl so as to obtain 10% of the weight of the total composition. The bag is then manually shaken for 5 minutes. The pre-mixture is then loaded in a mixer (Planetaria) together with the remainder of the ingredients and mixed for a period of 15 minutes at 120 rpm to obtain a homogeneous final composition.

The compositions listed in Table 1 have been administered to HL-1 cardiomyocytes and to immortalized brown adipocytes and the mitochondrial function has been evaluated as disclosed hereinafter.

METHODS

Cells and treatments

HL-1 cardiomyocytes

HL-1 cardiomyocytes (a gift from W.C. Claycomb, New Orleans, School of Medicine) were plated in fibronectin/gelatin-coated flasks, grown to 70%-80% confluence in Claycomb medium (JRH Biosciences) supplemented with 100 μ M norepinephrine (from a 10 mM norepinephrine [Sigma-Aldrich] stock solution dissolved in 30 mM L-ascorbic acid [Sigma-Aldrich]), 2 mM L-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin and 10% FBS (JRH Biosciences) as disclosed in Claycomb et al., 1998.

Cells were treated with 1% (w/v) of the compositions (dissolved in the Claycomb medium) shown in Table 1 for 24 hr or 48 hr.

At the end of these periods, mRNA and DNA were extracted from the cells or the cells were used to evaluate the oxygen consumption. Control cells were treated with Claycomb medium only.

Immortalized brown adipocytes

Immortalized brown adipocytes were purchased from Prof. Patrick Seale (University of Pennsylvania, Philadelphia, USA).

These are a SV40 immortalized BAT-derived cell line which, upon appropriate stimulation protocol, are able to differentiate in mature brown adipocytes.

Cells were routinely maintained in F12/DMEM (Gibco by
5 Life technologies) with 10% FBS; for differentiation, confluent cells were treated with medium containing 10% FBS plus 0.5 mM isobutylmethylxanthine, 125 nM indomethacin, 1 μ M dexamethasone, 20 nM insulin, 1 nM T3.

10 After 48 hr, cells switched to medium containing 10% FBS, 20 nM insulin, and 1 nM T3.

Preliminary experiments confirmed that 6-7 days of incubation with this medium are sufficient to induce the expression of UCP1 and other brown adipocyte
15 markers. In particular, expression of PRDM16, a 140 kDa PR (PRD1-BF1-RIZ1 homologous)-domain-containing protein that is a marker of brown adipocyte differentiation (Seale et al., 2007) was increased in differentiated cells. Therefore, after 6 days, cells were treated with
20 1% (w/v) different compositions shown in Table 1 (BCAAem, B2, α 5) dissolved in F12/DMEM. Control cells were fed with medium only. Then, after 48 hours, cells were harvested and RNA was extracted for gene expression analysis.

25 Gene Expression and Mitochondrial Biogenesis Methods

Total RNA was isolated from HL-1 cardiomyocytes and from immortalized brown adipocytes using the RNeasy Mini Kit (Qiagen); one microgram of total RNA was reverse transcribed in cDNA using the iScript cDNA
30 Synthesis Kit (Bio-Rad Laboratories) as described in D'Antona et al. (2010).

The gene relative level was calculated as 2^{-DDCT} , in which DDCT corresponded to the difference between the DCT of either treatment and the DCT of the untreated
35 group using GAPDH as internal control. The Delta-Delta-

CT (DDCT) algorithm is an approximation method to determine relative gene expression with quantitative real-time PCR (qRT-PCR) experiments (see Livak and Schmittgen, 2001).

- 5 Primers (sequence reported in Table 2 below) were designed using Beacon Designer 2.6 software (Premier Biosoft International). Values were normalized with the expression of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

10

Table 2

Gene	Primer	Sequence	SEQ ID.	T _a
GAPDH	Sense 5'-3'	AAC TTTGGCATTGTGGAAGG	No.1	60
	Antisense 5'-3'	ACACATTGGGGGTAGGAACA	No.2	
Cyt c	Sense 5'-3'	ATAGGGGCATGTCACCTCAAAC	No.3	61
	Antisense 5'-3'	GTGGTTAGCCATGACCTGAAAG	No.4	
PGC-1α	Sense 5'-3'	ACTATGAATCAAGCCACTACAGAC	No.5	61
	Antisense 5'-3'	TTCATCCCTCTTGAGCCTTTCG	No.6	
Tfam	Sense 5'-3'	AAGACCTCGTTCAGCATATAACATT	No.7	60
	Antisense 5'-3'	TTTTCCAAGCCTCATTTACAAGC	No.8	
KFL15	Sense 5'-3'	ACACCAAGAGCAGCCACCTCA	No.9	60
	Antisense 5'-3'	TGAGATCGCCGGTGCCTTGA	No.10	
PP2CM	Sense 5'-3'	ACCACAGGCAGGCGACTC	No.11	60
	Antisense 5'-3'	TGGCTCATCAATGCGGTTATCC	No.12	
mtDNA (12S rRNA)	Sense 5'-3'	ACATGCAAACCTCCATAGACCGG	No.13	63
	Antisense 5'-3'	TCACTGCTGAGTCCCGTGGG	No.14	
gDNA (GAPDH)	Sense 5'-3'	GGTCGCGGTGTGGGCATTTG	No.15	60
	Antisense 5'-3'	CGTGATCGTAGCGTCTGGTT	No.16	

T_a temperature of annealing (°C); Accession number GAPDH: NM_008084.3; Accession number Cyt c: NM_007808; Accession number PGC-1 α : AF049330; Accession number Tfam: NM_009360.4; Accession number KFL15: NM_023184.4; Accession number PP2CM: NM_175523.4; Mus musculus Mitochondrial, complete genome: NC_005089.1; gDNA (GAPDH): NC_000072.6; Primers code for 12S mitochondrial rRNA (NC_005098.1). GAPDH was used to normalize mitochondrial DNA.

15

For mitochondrial DNA (mtDNA) analysis, total DNA was extracted with QIAamp DNA extraction kit (QIAGEN).

mtDNA was amplified using primers specific for the
5 mitochondrial DNA (mtDNA) gene and normalized to
genomic DNA by amplification of GAPDH gene DNA.
Primers, designed using Beacon Designer 2.6 software
(Premier Biosoft International; Palo Alto, CA) are
shown in Table 2 for gDNA.

10 Statistical Analysis

For all gene expression data, two-sided paired-sample t
tests were used to compare values between control and
treated cells. A p value <0.05 was considered
statistically significant.

15 Oxygen consumption

An amount of 1 ml of HL-1 cardiomyocytes treated with
the compositions shown in Table 1 was re-suspended in
Hank's balanced salt solution (Sigma) and spun down to
pellet cells. A number of HL-1 cells was also
20 supplemented with a nitric oxide (NO) donor,
specifically with diethylenetriamine-NO also called
DETA-NO (Sigma-Aldrich, Milan, Italy), as positive
control.

Then, cells were re-suspended in a respiration buffer
25 (0.3 M mannitol, 10 mM KCl, 5 mM MgCl₂, 10 mM K₂PO₄, pH
7.4) at a density of 3.0×10^6 /ml.

Samples were analyzed at 37°C in a gas-tight vessel
equipped with a Clark-type oxygen electrode (Rank
Brothers Ltd.) connected to a chart recorder.

30 The oxygen electrode was calibrated assuming the
concentration of oxygen in the incubation medium as 200
μmol/l at 37°C.

Oxygen consumption was assessed with continuous mixing
for about ten minutes. The slope of the trace recorder
35 was then used to calculate oxygen consumption. Oxygen

content may vary depending on the amount of cells. Thus, protein content, which directly correlates with cell content, has been used to normalize the oxygen consumption in cell samples. Protein content was
5 determined by using the bicinchoninic acid protein (BCA) assay.

RESULTS

HL-1 cardiomyocytes Mitochondrial DNA (mtDNA)

The mitochondrial DNA (mtDNA) was first evaluated in
10 the cells treated with the different amino acids compositions in order to verify their effects on mitochondrial mass.

As shown in Fig.1, HL-1 cardiomyocytes treated with $\alpha 5$ composition showed the most significant increase in
15 mtDNA with respect to the mtDNA evaluated in control cells (CT), in B2-treated cells and, very interestingly, in cells treated with the BCAAem composition.

HL-1 cardiomyocytes PGC-1 α , Tfam and Cyt c

20 The effect of the different amino acid compositions was also tested on mitochondrial biogenesis. Specifically, the expression by HL-1 cardiomyocytes of the following markers was evaluated:

- peroxisome proliferator-activated receptor gamma
25 coactivator 1-alpha (PGC-1 α), the master regulator of mitochondrial biogenesis,
- mitochondrial DNA transcription factor A (Tfam), the mtDNA transcription factor regulating mtDNA replication,
- 30 - cytochrome complex (Cyt c), the respiratory complex protein.

Comparison between the results obtained following the administration of the BCAAem composition, the B2 composition (i.e. the composition similar to the BCAAem
35 composition but also comprising citric acid), $\alpha 5$ (i.e.

the composition comprising as active agent other than amino acids also the acids citric acid, succinic acid, malic acid) showed that the $\alpha 5$ composition was the most effective in promoting the expression of the above markers in HL-1 cardiomyocytes cells.

Moreover, a time-course effect was observed: after a supplementation of 48 hr with the $\alpha 5$ composition comprising amino acids listed in Table 1 together with the three carboxylic acids indeed the increase was still more pronounced over the basal values.

The increase was also statistically significant with respect to the value of the BCAAem composition for Tfam when compared to 24 hr treatment (Fig. 2) and for PGC-1 α and for Cyt c after 48 hr treatment (Fig. 3).

HL-1 cardiomyocytes KFL15 and PP2CM

Krüppel-like factor 15 (KFL15) and mitochondrial matrix-targeted protein phosphatase 2C family member (PP2CM) are proteins that regulate the catabolism of the branched chain amino acids (BCAA).

The first steps in BCAA catabolism are common to the three BCAAs and require the mitochondrial enzymes BCAA aminotransferase (BCAT) and branched-chain α -keto acid dehydrogenase complex (BCKDC).

In the first and fully reversible step of degradation, mitochondrial BCAT transfers the amino group from BCAAs to α -ketoglutarate to form the corresponding branched-chain α -keto acids (BCKAs) and glutamate.

Thereafter, BCKDC catalyses decarboxylation of the carboxyl groups of BCKAs, to form the corresponding branched-chain acyl-CoA esters.

This reaction is irreversible and, therefore, commits the BCAAs to degradation.

BCKDC activity is regulated by end-product allosteric inhibition by NADH, α -ketoisocaproate, and branched-chain acyl-CoA esters.

BCKDC activity is determined by the phosphorylation status of its regulatory subunit Ela.

When the BCAA level is low, Ela is hyper-phosphorylated by a BCKD kinase, leading to inhibition of BCKDC
5 activity and preservation of free BCAA.

When the BCAA level is high, Ela is dephosphorylated by a mitochondrial-targeted 2C-type Ser/Thr protein phosphatase named PP2C in mitochondria (PP2CM) or protein phosphatase, Mg²⁺/Mn²⁺ dependent 1K (PPM1K),
10 leading to BCKDC activation and reducing total BCAAs (Bifari and Nisoli, 2016).

In addition, KLF15 was found to increase BCAT, BCKDC, and PP2CM gene expression in heart (Sun et al., 2016).

The evaluation of the mRNA levels of PP2Cm and KLF13
15 showed that $\alpha 5$ composition increased PP2CM and KLF15 mRNA levels over the basal value in HL-1 cardiomyocytes. The increase was significant even over BCAAem composition (Fig. 4)

These results shows that compositions comprising an
20 active agent, the active agent containing leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid and malic acid, are very effective in promoting mitochondrial function and activate more efficiently mitochondrial biogenesis even with respect
25 to the BCAAem composition in metabolically active cells.

HL-1 cardiomyocytes Oxygen consumption (OCR)

Oxygen consumption of HL-1 cells supplemented with different compositions was tested. Cells supplemented
30 with diethylenetriamine-NO (DETA-NO) as positive control were also tested. The effect of DETA-NO on increasing the cell oxygen consumption has been shown (Nisoli et al., 2003). NO was found to trigger mitochondrial biogenesis in cells as diverse as brown
35 adipocytes and 3T3-L1, U937, and HeLa cells. This

effect of nitric oxide was dependent on cyclic guanosine 3',5'-monophosphate (cGMP) and was mediated by the induction of PGC-1 α , a master regulator of mitochondrial biogenesis (Nisoli et al., 2003).

5 After 48h of DETA-NO treatment, a rise of oxygen consumption was observed, as expected.

Most notably, a markedly increase in oxygen consumption was observed when HL-1 cells were supplemented with α 5 composition for 48 hr thus indicating a rise in
10 mitochondrial activity (Fig. 5).

The increase is significantly higher than that observed after B2 and BCAAem compositions administration.

UCP1 expression in immortalized brown adipocytes

As shown in Fig. 6, 48 hours treatment with the
15 disclosed compositions increased, albeit to different extents, UCP1 expression in immortalized brown adipocytes.

Among different mixtures, α 5 was the most effective in inducing UCP1 expression with respect to untreated
20 cells ($p = 0,04$ vs CT); α 5 also increased UCP1 mRNA more efficiently when compared to BCAAem mixture ($p = 0,05$).

PGC-1 α expression in immortalized brown adipocytes

In line with UCP1 data, α 5 mixture also significantly
25 increased expression of PGC-1 α ($p = 0,01$), thus confirming the capability of this composition in activating mitochondrial biogenesis (Fig. 7). Of note, α 5 was also more effective than BCAAem composition in increasing PGC-1 α expression.

30 Taken together, these results indicate that compositions comprising an active agent, the active agent containing a combination of leucine, isoleucine, valine, threonine, lysine, citric acid, succinic acid and malic acid is significantly more active in

promoting mitochondrial biogenesis, mitochondrial function and BCAA catabolism.

The composition $\alpha 6$ ($\alpha 6$) and $\alpha 7$ ($\alpha 7$), providing for an active ingredient comprising the
5 BCAAs, threonine and lysine, as well as citric acid, succinic acid and malic acid are believed to attain similar advantages.

Of note, catabolism of BCAA, which are enriched in the mixture, in addition to Acetyl-CoA, provides succinyl-
10 CoA. This latter could activate succinyl-CoA synthetase reaction, which, in turn produces succinate as a substrate for the subsequent reaction of succinate dehydrogenase.

Providing succinate, along with BCAA, in the mixture
15 could therefore also stimulate the succinate dehydrogenase reaction, thus further boosting the cycle. Of note, succinate dehydrogenase, by directly providing $FADH_2$, is also part of mitochondrial the electron transport chain (complex II). Its stimulation
20 by succinate could therefore directly activate mitochondrial redox carriers and increase membrane potential, thus enhancing proton gradient, oxygen consumption and ATP synthesis.

At the same time, malate supplement could activate
25 malate dehydrogenase reaction and increase NADH levels; this would also provide substrates for complex I and therefore increase ATP levels, in the same manner as succinate-derived $FADH_2$. On the other hand, malate could stimulate the activity of malate-aspartate
30 shuttle. This would favour the entry of also cytosolic NADH into mitochondria, which would otherwise be impermeable through mitochondrial membrane, thus rendering it available for mitochondrial oxidation. This would further increase mitochondrial activity and
35 oxygen consumption.

In addition, energy obtained from the breakdown of carbohydrates or fats is derived by the process of mitochondrial oxidative phosphorylation. Catabolism of glucose and fatty acids by TCA (tricarboxylic acid) cycle provides NADH and FADH₂ molecules. Electrons from NADH and FADH₂ are then transferred to molecular oxygen through protein complexes in the inner mitochondrial membrane and this process generated a proton gradient across the mitochondrial membrane. Protons re-entry into mitochondria through ATP synthase complex, which uses energy from the gradient to synthesize adenosine triphosphate (ATP). In this way, electron transport is coupled to ATP synthesis.

On the other hand, UCP1, a mitochondrial transmembrane protein which is activated in BAT after cold or excess nutrients, dissipates proton gradient across the mitochondrial inner membrane, and this results in the uncoupling of oxidative phosphorylation. Energy derived from proton gradient is no more available for ATP synthesis and, since UCP1 do not form ATP, energy from the proton gradient is therefore liberated as heat.

Increased mitochondrial biogenesis and number also underlies the thermogenic program which occurs in BAT in response to the above mentioned stimuli, and a key role in this process is played by Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α), a cold-inducible transcriptional coactivator able to regulate the expression of both UCP1 and other factors involved in mitochondrial biogenesis (Scarpulla, 2011). Consequently, stimulation of UCP1 activity and heat production in BAT could be a potential therapeutic approach for reversing obesity, and there is great interest for searching agents and/or nutritional strategies that would stimulate the activity of this tissue.

It is also noteworthy that, more recently, a third type of fat, besides WAT and BAT, has been recognized in some WAT depots and has been described as beige or "brite" fat. In response to the same stimuli which
5 induce thermogenesis in BAT, this tissue undergoes the process of "browning", by enhancing the expression of thermogenic proteins, such as UCP1, and by also inducing typical brown fat markers and, consequently, leading to an enhancement of energy expenditure (EE,
10 Song et al., 2017). These findings, therefore, challenge the common view of WAT as a metabolically inert organ and strengthen the hypotheses of a more plastic and "druggable" target tissue, making thus brite fat another potential target for an anti-obesity
15 therapeutic or nutritional approach.

Altogether, these results show that the compositions herein disclosed are able to increase mitochondrial biogenesis and function, BCAA catabolism in HL-1 cardiomyocytes and to promote brown adipocytes markers
20 expression.

From the foregoing, it emerges clearly how the compositions according to the instant disclosure are useful for the treatment of pathological conditions distinguished by insufficient mitochondrial function in
25 humans and in animals.

REFERENCES

- Bifari F, Nisoli E. Branched-chain amino acids differently modulate catabolic or anabolic states in mammals: a pharmacological point of view. Br J Pharmacol. 2016 Sep 17. doi: 10.1111/bph.13624. [Epub ahead of print].
- Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004 Jan;84(1):277-359. Review
- Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95: 2979-2984, 1998.
- D'Antona G, Ragni M, Cardile A, Tedesco L, Dossena M, Bruttini F, Caliaro F, Corsetti G, Bottinelli R, Carruba MO, Valerio A, Nisoli E. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab. 12: 362-372, 2010.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
- Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science: 299(5608):896-9, 2003.

Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO. Calorie restriction promotes
5 mitochondrial biogenesis by inducing the expression of eNOS. Science 310: 314-317, 2005.

Seale P, Kajimura S, Yang W, Chin S, Rohas LM, Uldry M, Tavernier G, Langin D, Spiegelman BM. Transcriptional
10 control of brown fat determination by PRDM16. Cell Metab. 6: 38-54, 2007

Song NJ et al. Induction of thermogenic adipocytes: molecular targets and thermogenic small molecules. Exp
15 Mol Med. 2017 Jul 7;49(7):e353. doi: 10.1038/emmm.2017.70. Review. PubMed PMID: 28684864.

Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, Jeyaraj D, Youn JY, Ren S, Liu Y, Rau CD, Shah S,
20 Ilkayeva O, Gui WJ, William NS, Wynn RM, Newgard CB, Cai H, Xiao X, Chuang DT, Schulze PC, Lynch C, Jain MK, Wang Y. Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation 133: 2038-2049, 2016.

25 Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813(7):1269-78

30 Trayhurn P. Recruiting Brown Adipose Tissue in Human Obesity. Diabetes. 2016;65(5):1158-60.

Wells GD, Noseworthy MD, Hamilton J, Tarnopolski M, Tein I. Skeletal muscle metabolic dysfunction in
35 obesity and metabolic syndrome. Can J Neurol Sci.

2008;35 (1):31-40. Review

World Health Organization. Obesity and overweight. WHO Media Centre. Updated August 2014. Available from
5 <http://www.who.int/mediacentre/factsheets/fs311/en/>.

CLAIMS

1. Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.
2. Composition according to claim 1, wherein the weight ratio between the sum of citric acid, malic acid, succinic acid and the sum of the branched chain amino acids leucine, isoleucine, valine plus lysine and threonine is comprised between 0.05 and 0.3, preferably between 0.1 and 0.25.
3. Composition according to any one of the preceding claims, wherein the weight ratio between the overall amount of citric acid, malic acid, succinic acid and the overall amount of the branched chain amino acids leucine, isoleucine, valine is comprised between 0.1 and 0.4, preferably between 0.15 and 0.35.
4. Composition according to any one of the preceding claims, wherein the weight ratio between citric acid and the sum of malic acid and succinic acid is comprised between 1.0 and 4.0, preferably between 1.5 and 2.5.
5. Composition according to any one of the preceding claims, wherein the citric acid:malic acid:succinic acid weight ratio is comprised between 10:1:1 and 2:1.5:1.5, preferably between 7:1:1 and 1.5:1:1, more preferably between 5:1:1 and 3:1:1.

6. Composition according to any one of the preceding claims, wherein said active agent further comprises at least one amino acid selected in the group consisting of histidine, phenylalanine, methionine, tryptophan, tyrosine, cysteine.

7. Composition according to any one of the preceding claims, wherein said active agent further comprises histidine, phenylalanine, methionine, tryptophan, cysteine and optionally tyrosine.

8. Composition according to any one of the preceding claims, the ratio between the overall molar amount of citric acid, malic acid, succinic acid and the overall molar amount of methionine, phenylalanine, histidine and tryptophan is higher than 1.35.

9. Composition according to any one of the preceding claims, wherein the ratio between the overall molar amount of the three acids citric acid, succinic acid, malic acid and the overall molar amount of lysine and threonine is comprised between 0.1 and 0.7, preferably between 0.15 and 0.55.

10. Composition according to any one of the preceding claims, wherein the weight or molar amount of citric acid is higher than the overall weight or molar amount of malic acid and succinic acid.

11. Composition according to any one of the preceding claims, wherein the weight ratio between leucine and citric acid is comprised between 5 and 1, preferably between 2.50 and 3.50.

12. Composition according to any one of the

preceding claims, wherein said active agent is free of arginine.

5 **13.** Composition according to any one of the preceding claims, wherein the composition further comprises one or more vitamins, preferably selected in the group of vitamins B, more preferably vitamin B1 and/or vitamin B6.

10 **14.** Composition according to any one of claims 1 to 13, for use in medicine.

15 **15.** Composition according to any one of claims 1 to 14, for use in the treatment and/or prevention of a mitochondrial dysfunction-related disease, wherein the mitochondrial dysfunction-related disease is obesity.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figura 6




Figura 7

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2018/055428

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/194 A61K31/198 A61P3/04
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2016/179657 A1 (NEWCASTLE INNOVATION LTD [AU]) 17 November 2016 (2016-11-17) paragraphs [0012], [0023], [0025], [0050], [0104], [0122], [0124], [0143], [0144], [0145] -----	1-15
Y	WO 2017/020121 A1 (VAL-CHUM LTD PARTNERSHIP [CA]) 9 February 2017 (2017-02-09) page 18, line 3 - page 22, line 19; claims 1-33 -----	1-15
Y	WO 2017/089612 A1 (DOUBLEGOOD AB [SE]) 1 June 2017 (2017-06-01) page 2, line 29 - page 4, line 5 page 5, line 39 - page 8, line 10 ----- -/--	1-15

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 October 2018

Date of mailing of the international search report

06/11/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Markopoulos, Etyxia

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2018/055428

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2014/315788 A1 (WOLFE ROBERT R [US] ET AL) 23 October 2014 (2014-10-23) paragraphs [0005] - [0008], [0019], [0020], [0025], [0029], [0034], [0035], [0042], [0048] - [0050]; examples 3,4; tables A,B,C -----	1-15
Y	US 2013/237605 A1 (ZEMEL MICHAEL [US] ET AL) 12 September 2013 (2013-09-12) paragraphs [0004] - [0023], [0063] - [0071], [0079] -----	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2018/055428

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☐ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2018/055428

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016179657 A1	17-11-2016	AU 2016262125 A1 CN 107708683 A EP 3294281 A1 JP 2018520204 A KR 20180029963 A US 2018161296 A1 WO 2016179657 A1	30-11-2017 16-02-2018 21-03-2018 26-07-2018 21-03-2018 14-06-2018 17-11-2016
WO 2017020121 A1	09-02-2017	US 2018221457 A1 WO 2017020121 A1	09-08-2018 09-02-2017
WO 2017089612 A1	01-06-2017	AU 2016360831 A1 CN 108366610 A EP 3379946 A1 KR 20180084069 A WO 2017089612 A1	14-06-2018 03-08-2018 03-10-2018 24-07-2018 01-06-2017
US 2014315788 A1	23-10-2014	US 2014315788 A1 US 2017143679 A1	23-10-2014 25-05-2017
US 2013237605 A1	12-09-2013	AU 2013229779 A1 AU 2018200861 A1 CA 2866718 A1 EP 2822579 A1 HK 1205942 A1 JP 6210517 B2 JP 2015510888 A JP 2018012722 A US 2013237605 A1 US 2016113317 A1 US 2017000777 A1 US 2017368045 A1 WO 2013134736 A1	23-10-2014 22-02-2018 12-09-2013 14-01-2015 31-12-2015 11-10-2017 13-04-2015 25-01-2018 12-09-2013 28-04-2016 05-01-2017 28-12-2017 12-09-2013